![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 10
2022
Hofmann, Felix O. 
ORCID: https://orcid.org/0000-0002-6913-2429; Heinemann, Volker; D'Anastasi, Melvin; Gesenhues, Alena B.; Hesse, Nina; Weikersthal, Ludwig Fischer von; Decker, Thomas; Kiani, Alexander; Moehler, Markus; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Link, Hartmut; Modest, Dominik P.; Stintzing, Sebastian und Holch, Julian W.
(2022):
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3/AIO KRK-0306.
In: European Radiology, Bd. 33, Nr. 2: S. 1174-1184
[PDF, 2MB]
ORCID: https://orcid.org/0000-0002-6913-2429; Heinemann, Volker; D'Anastasi, Melvin; Gesenhues, Alena B.; Hesse, Nina; Weikersthal, Ludwig Fischer von; Decker, Thomas; Kiani, Alexander; Moehler, Markus; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Link, Hartmut; Modest, Dominik P.; Stintzing, Sebastian und Holch, Julian W.
(2022):
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3/AIO KRK-0306.
In: European Radiology, Bd. 33, Nr. 2: S. 1174-1184
[PDF, 2MB]
Fischer, Laura E. ORCID: https://orcid.org/0000-0001-8752-5827; Stintzing, Sebastian; Weikersthal, Ludwig Fischer von; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2022):
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
In: British Journal of Cancer, Bd. 127, Nr. 5: S. 836-843
[PDF, 788kB]
ORCID: https://orcid.org/0000-0001-8752-5827; Stintzing, Sebastian; Weikersthal, Ludwig Fischer von; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2022):
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
In: British Journal of Cancer, Bd. 127, Nr. 5: S. 836-843
[PDF, 788kB]
2021
Liu, Lian; Erickson, Nicole Tonya; Ricard, Ingrid; Weikersthal, Ludwig Fischer von; Lerch, Markus M.; Decker, Thomas; Kiani, Alexander; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Link, Hartmut; Hoeffkes, Heinz-Gert; Moehler, Markus; Gesenhues, Alena Britta; Theurich, Sebastian; Michl, Marlies; Modest, Dominik P.; Alguel, Hana; Stintzing, Sebastian; Heinemann, Volker und Holch, Julian W.
(2021):
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
In: International Journal of Cancer, Bd. 150, Nr. 1: S. 112-123
2020
Stahler, Arndt; Stintzing, Sebastian; Einem, Jobst C. von; Westphalen, Christoph B.; Heinrich, Kathrin; Kraemer, Nicole; Michl, Marlies; Modest, Dominik P.; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Moehler, Markus; Kaiser, Florian; Kirchner, Thomas; Jung, Andreas und Heinemann, Volker
(2020):
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.
In: European Journal of Cancer, Bd. 137: S. 250-259
Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Kaiser, Florian; Al-Batran, Salah-Edin; Heintges, Tobias; Lerchenmüller, Christoph; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Moehler, Markus; Scheithauer, Werner; Held, Swantje; Miller-Phillips, Lisa; Modest, Dominik Paul; Jung, Andreas; Kirchner, Thomas und Stintzing, Sebastian
(2020):
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
In: British Journal of Cancer, Bd. 124, Nr. 3: S. 587-594
Schulz, Christoph; Heinemann, Volker; Heinrich, Kathrin; Haas, Michael; Holch, Julian W.; Fraccaroli, Alessia; Held, Swantje; Einem, Jobst C.von; Modest, Dominik P.; Fischer von Weikersthal, Ludwig; Kullmann, Frank; Moehler, Markus; Scheithauer, Werner; Jung, Andreas und Stintzing, Sebastian
(2020):
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
In: Anti-Cancer Drugs, Bd. 31, Nr. 8: S. 856-865
2018
Holch, Julian W.; Ricard, Ingrid; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Scholz, Michael; Müller, Sebastian; Link, Hartmut; Rost, Andreas; Höffkes, Heinz-Gert; Moehler, Markus; Lindig, Reinhard Udo; Miller-Phillips, Lisa; Kirchner, Thomas; Jung, Andreas; Einem, Jobst C. von; Modest, Dominik Paul und Heinemann, Volker
(2018):
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
In: International Journal of Cancer, Bd. 142, Nr. 5: S. 1047-1055
2017
Modest, Dominik P.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Scheithauer, Werner; Kirchner, Thomas; Jung, Andreas; Stauch, Martina; Einem, Jobst Christian von; Möhler, Markus; Held, Swantje und Heinemann, Volker
(2017):
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
In: International Journal of Cancer, Bd. 140, Nr. 8: S. 1918-1925
2016
Modest, Dominik Paul; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Sobrero, Alberto F.; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Seipelt, Gernot; Lerchenmüller, Christian A.; Kahl, Christoph; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Moehler, Markus H.; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2016):
Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab).
In: Journal of Clinical Oncology, Bd. 34, Nr. 4
Stintzing, Sebastian; Modest, Dominik P.; Rossius, Lisa; Lerch, Markus M.; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Giessen-Jung, Clemens; Moehler, Markus; Jagenburg, Andreas; Kirchner, Thomas; Jung, Andreas und Heinemann, Volker
(2016):
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
In: Lancet Oncology, Bd. 17, Nr. 10: S. 1426-1434